# Formation Bio Drug Development Accelerator Fund

> Formation Bio announced $600M in commitments to its debut drug-asset fund in October 2026. It aims to acquire or license 10–15 Phase 1/2 programs over 3–5 years, with each asset housed in a NewCo. Formation Bio acts as GP through a subsidiary. Individual LPs, fees and final-close status were not disclosed. This is fund capital, not corporate equity.

## Profile

- **Stage-based planning range:** $100K–$1M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** N/A
- **AUM:** N/A
- **Rounds they lead:** N/A
- **Rounds they invest:** N/A

## Links

- [Website](https://www.formation.bio/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/formation-bio-drug-development-accelerator-fund